Altered arginine metabolism in Alzheimer's disease brains

Liu, Ping; Fleete, Michael S.; Yu, Jing; Collie, Nicola D.; Curtis, Maurice A.; Waldvogel, Henry J.; Faull, Richard L.M.; Abraham, Wickliffe C.; Zhang, Hu

doi:10.1016/j.neurobiolaging.2014.03.013

Cited by 148 publications

(145 citation statements)

References 87 publications

Supporting

Mentioning

128

Contrasting

Order By: Relevance

“…Therefore, ornithine and its metabolites may participate in the pathomechanisms of PD. Consistent with our results, previous studies suggested that the polyamine pathway may participate in the aetiology and pathology of neuropsychiatric diseases, such as schizophrenia, mood disorders, anxiety and Alzheimer disease 37 38…”

Section: Discussionsupporting

confidence: 92%

Identification of novel biomarkers for Parkinson's disease by metabolomic technologies

Hatano

Saiki

Okuzumi

et al. 2015

J Neurol Neurosurg Psychiatry

207

179

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Identification of novel biomarkers for Parkinson's disease by metabolomic technologies

Hatano

Saiki

Okuzumi

et al. 2015

J Neurol Neurosurg Psychiatry

207

179

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence suggests a prominent role of altered arginine metabolism in the pathogenesis of AD (Law et al, 2001;Yi et al, 2009;Minois et al, 2011;Toda and Okamura, 2012;Inoue et al, 2013;Liu et al, 2014;Whiteley, 2014). The main finding of the present study is that a single i.c.v.…”

Section: Discussionsupporting

confidence: 62%

“…However Ab has recently been considered as a consequence, rather than the cause, of AD (Drachman, 2014). There is increasing evidence suggesting the prominent role of altered arginine metabolism in AD pathogenesis (Law et al, 2001;Yi et al, 2009;Minois et al, 2011;Toda and Okamura, 2012;Inoue et al, 2013;Liu et al, 2014;Whiteley, 2014). It has been suggested that cerebrovascular endothelial dysfunction (hence reduced cerebral blood flow) during advanced aging triggers the neurodegenerative process in AD (de la Torre and Stefano, 2000;Aliev et al, 2009).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, there is a growing body of evidence suggesting the involvement of arginine metabolism in AD pathogenesis (Law et al, 2001;Yi et al, 2009;Minois et al, 2011;Toda and Okamura, 2012;Inoue et al, 2013;Liu et al, 2014;Whiteley, 2014). Liu et al (2014) systematically compared the metabolic profile of L-arginine in the superior frontal gyrus, hippocampus and cerebellum from AD (mean age 80 years) and normal (mean age 80 or 60 years) cases.…”

Section: Introductionmentioning

confidence: 99%

“…Liu et al (2014) systematically compared the metabolic profile of L-arginine in the superior frontal gyrus, hippocampus and cerebellum from AD (mean age 80 years) and normal (mean age 80 or 60 years) cases. There were down-regulations in constitutive nNOS and eNOS, but up-regulations in iNOS and arginase (particularly arginase II), and altered concentrations of L-arginine and its downstream metabolites in AD brains in a metabolite-and/or regionspecific manner.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A single intracerebroventricular Aβ25–35 infusion leads to prolonged alterations in arginine metabolism in the rat hippocampus and prefrontal cortex

Bergin

Zhang

et al. 2015

Neuroscience

View full text Add to dashboard Cite

A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease

Lin

Huang

et al. 2019

Ann Clin Transl Neurol

View full text Add to dashboard Cite

Objective This study aims to identify metabolites with altered levels of expression in patients with early and progressive stages of Alzheimer's disease (AD). Methods All participants of the study underwent genetic screening and were diagnosed using both neuropsychological assessment and amyloid imaging before metabolome analysis. According to these assessments, the patients were classified as normal (n = 15), with mild cognitive impairment (n = 10), and with AD (n = 15). Results Using a targeted metabolomic approach, we found that plasma levels of C3, C5, and C5‐DC acylcarnitines, arginine, phenylalanine, creatinine, symmetric dimethylarginine (SDMA) and phosphatidylcholine ae C38:2 were significantly altered in patients with early and progressive stages of AD. We created a predictive model based on the decision tree that included three main parameters: age, arginine and C5 plasma concentrations. The model distinguished AD patients from other participants with 60% sensitivity and 86.7% specificity. For healthy controls, the sensitivity was 85.7% and specificity was 61.5%. Multivariate ROC analysis to develop a decision tree showed that our model reached moderate diagnostic power in differentiating between older adults who are cognitively normal (AUC = 0.77) and those with AD (AUC = 0.72). Interpretation The plasma levels of arginine and valeryl carnitine, together with subject age, are promising as biomarkers for the diagnosis of AD in older adults.

show abstract

Altered arginine metabolism in Alzheimer's disease brains

Cited by 148 publications

References 87 publications

Identification of novel biomarkers for Parkinson's disease by metabolomic technologies

Identification of novel biomarkers for Parkinson's disease by metabolomic technologies

A single intracerebroventricular Aβ25–35 infusion leads to prolonged alterations in arginine metabolism in the rat hippocampus and prefrontal cortex

A metabolomic approach to identifying biomarkers in blood of Alzheimer's disease

Contact Info

Product

Resources

About